Abstract Tumorigenic activity of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in the production of prostaglandins (PGs), has been proved for some types of cancer, including brain tumors. We evaluated expression of COX-2 in meningioma, one of the most common intracranial tumors in adults which accounts for 24-30 % of intracranial tumors. We performed immunostaining for COX-2 in 76 cases of meningioma consisting of 44 cases of low-grade (WHO Grade I) and 32 cases of high-grade (29 cases of Grade II and 3 cases of Grade III) meningioma, and evaluated COX-2 expression levels on the basis of staining intensity and proportion in tumor cells. The expression level of COX-2 in meningioma cells was significantly correlated with WHO grade (P = 0.0153). In addition, COX-2 expression was significantly correlated with MIB-1 labeling index for all 76 cases of meningioma (P = 0.0075), suggesting tumor promotion by COX-2 in meningioma progression. Our results may indicate the therapeutic value of non-steroidal anti-inflammatory drugs against meningioma, especially for patients with elevated proliferation, to regulate the tumorigenic activity of COX-2 in meningioma cells.
Introduction
Meningioma is one of the most common intracranial tumors in adults, and accounts for 24-30 % of brain tumors [1, 2] . In the 2007 World Health Organization (WHO) classification, meningiomas are histologically classified into Grades I, II, and III [3] , and approximately 90 % of meningiomas are low-grade (Grade I) benign tumors; however, approximately 10 % are classified as high-grade (Grade II or III), with unfavorable clinical course [2] . For Grade II and III meningiomas the risk of recurrence after surgical resection is 30-40 % and 50-80 %, respectively [4] , and five-year survival for Grades II and III are 67.5 % and 60 %, respectively [5] . In addition, even low-grade meningiomas of Grade I sometimes recur, and/or malignant progression is observed [4, 6] . Therapy for high-grade meningioma includes surgical resection, preoperative embolization, adjuvant radiotherapy, and multidrug chemotherapy. However, treatment efficacy, especially of chemotherapy, is limited, and there is currently no standard treatment for recurrent high-grade meningiomas after surgery and radiation therapy. Thus proper diagnosis of high-grade meningioma on the basis of reliable molecular markers is required by neuropathologists and neurosurgeons to enable treatment of patients with high-grade meningioma and recurrent benign meningioma.
Cyclooxygenase-2 (COX-2), a rate-limiting enzyme in the production of prostaglandins (PGs), is induced in response to mitogens and pro-inflammatory cytokines [7, 8] . An important event in the development of cancer is overexpression of COX-2. In particular, the tumorigenic action of COX-2 and its products, for example PGE 2 and PGF 2 a, during colorectal cancer development have been well described [9] [10] [11] [12] [13] [14] [15] . A correlation between COX-2 expression and MIB-1 labeling index has also been shown for breast, renal, and gastric cancers [16] [17] [18] . Moreover, long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), for example sulindac or aspirin, to inhibit COX is associated with a 40-50 % reduction in the incidence of colon adenomas and carcinomas [19] [20] [21] . Although expression of COX-2 has also been associated with brain tumors, including glioma and meningioma [22, 23] , the number of studies is limited and the clinicopathological value of COX-2 expression is still controversial, especially for meningioma.
We performed immunohistochemical analysis of COX-2 expression for 76 cases of meningioma, including 32 highgrade cases, to investigate the clinicopathological and prognostic value of COX-2 expression in meningioma.
Materials and methods

Patients
The study was performed with the approval of the Internal Review Board on Ethical issues of Hokkaido University Graduate School of Medicine, Sapporo, Japan. Samples and the patients' information were obtained after obtaining complete written informed consent. The subjects of this study were 76 patients who underwent surgery for meningioma between 2005 and 2012 at Hokkaido Neurosurgical Memorial Hospital, Sapporo Azabu Neurosurgical Hospital, Kashiwaba Neurosurgical Hospital, Nakamura Memorial Hospital, Sapporo, Japan, and Hokuto Hospital, Obihiro, Japan.
Outcomes for patients were analyzed as overall survival (OS) and progression-free survival (PFS). OS was defined as the time from surgery to death from any cause and PFS as the time from surgery to first evidence of progression of disease or death from any cause. Mean post-operative was 19.4 months (range 1.4-108.8 months). Mean follow-up time was 23.7 months (range 1.4-108.8 months). Detail of each patient are shown in Supplemental Table 1 .
Classification methods
All patients were first classified in accordance with the WHO Classification of Tumors of the Central Nervous System (4th edition). Routinely formalin-fixed, paraffinembedded, tissue sections of tumors were stained with hematoxylin and eosin (H&E) and used for pathological diagnosis.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded sections of meningioma specimens. After deparaffinization and dehydration, specimens were brought to the boil in EDTA buffer (pH 9.0). Anti-COX2 antibody (Cayman Chemical, Michigan, USA; polyclonal, 1:100 dilution) and anti-Ki67 (Dako, Tokyo, Japan; Clone MIB-1, M7240, 1:100 dilution) were incubated at 4°C overnight, and reacted with a dextran polymer reagent combined with secondary antibodies and peroxidase (Envision/HRP; Dako). Each slide was evaluated independently by three pathologists (Y. K., H. M., and H. N.). Immunostaining of COX-2 was evaluated in terms of the proportion and staining intensity of tumor cells. The proportion was assessed on the basis of the percentage of immunopositive cells as follows: 0, 0 %; ?1, less than 10 %; ?2, 10-50 %; and ?3, greater than 50 %. Staining intensity was evaluated as weak (?1), moderate (?2), or strong (?3). When the sum of the proportion score and intensity score was more than 4 (range 0-6), we evaluated it as ''high level'' of COX-2 in tumor cells. The MIB-1 labeling index was calculated as representative of maximum activity and evaluated by counting the percentage of positive nuclei in a high-powered field of the whole neoplastic lesion; all degrees of nuclear staining intensity were taken into consideration.
Statistical analysis were analyzed by use of Pearson's chi-squared test and Spearman's rank correlation coefficient.
Results
Patients' characteristics
The clinicopathological characteristics of these cases are summarized in Table 1 . Mean age of patients was 60.3 years (range 17-90). Twenty-three patients (30.3 %) were males. The number of the patients with WHO Grade I meningioma was 44 (57.9 %), with Grade II meningioma was 29 (38.2 %), and with Grade III meningioma was 3 (3.9 %). The histological subtypes of meningioma varied as shown in Table 1 . Representative H&E sections are shown in Fig. 1 and Supplemental Fig. 1 .
COX-2 expression in meningioma cells according to WHO grade
To confirm the specificity of COX-2 staining, we compared COX-2 immunoreactivity in meningioma cells with that in colon cancer cells in which COX-2 expression had been confirmed in a previous study [24] . Similar COX-2 staining was observed in meningioma and colon cancer cells (Supplemental Fig. 2 ). We also observed distinct expression of COX-2 in macrophages which were identified in tumor stroma ( Fig. 1 and Supplemental Fig. 2) . We also performed reverse transcription polymerase chain reaction (RT-PCR) and detected COX-2 mRNA in tissue sections of meningioma (Supplemental Fig. 2 ). We finally concluded that COX-2 staining in meningioma was suitable for evaluation of COX-2 expression in meningioma cells. For objective evaluation of COX-2 by immunohistochemistry, we used the immunohistochemical scoring system discussed in ''Materials and methods'', in which the total score was obtained as the sum of the proportion and intensity scores; the results are shown in Table 2 . COX-2 was identified in the cytoplasm of meningioma and inflammatory cells (Fig. 1b, f, j) . Among the 76 cases, 19 cases (25.0 %) had a total score of 0, meaning absence of COX-2 expression, and 37 cases (48.7 %) were categorized as high-level COX-2 because of a total score of more than 4. We divided the 76 cases into low (Grade I) and highgrade (Grade II, III), and compared COX-2 expression level according to immunohistochemical total score (Table 3 and Supplemental Fig. 3) . As a result, COX-2 expression level was statistically correlated with WHO grade in meningioma by use of Pearson's chi-squared test (P = 0.0153); i.e., high-grade meningiomas express much higher levels of COX-2 in tumor cells.
Correlation of COX-2 expression with MIB-1 labeling index in meningioma
We performed immunostaining for 76 cases with Ki-67 antibody to obtain the MIB-1 labeling index as a cell proliferation index and compare it with COX-2 expression level. Representative pictures of immunohistochemistry are shown in Fig. 2a-d , and the distribution of the MIB-1 labeling index according to the total COX-2 score is Fig. 2e and Table 3 . Scatter plot analysis revealed a significant relationship between COX-2 expression level and MIB-1 labeling index (R 2 = 1.0) (Fig. 2e) . In addition, the Spearman's rank correlation coefficient confirmed this result (Table 3) .
Discussion
Excessive expression of COX-2 and its prognostic use have been discussed for different types of cancer, for example colon [24] [25] [26] , breast [27, 28] , and lung cancer [29] . For meningeal tumor, only 4 previous studies reported immunohistochemical expression of COX-2 [22, [30] [31] [32] and only one report among them revealed a statistical correlation between COX-2 expression and WHO grade in meningioma [22] . However, this result was based on meningioma grade by the previous version of the WHO classification for brain tumor (2nd edition; 1993); the statistical value was diminished when the updated WHO classification (3rd edition; 2000) was used [22] . Our study is the first report of COX-2 expression according to . We also sought evidence that COX-2 expression level was also correlated with the MIB-1 labeling index of meningioma, suggesting that COX-2 was of crucial importance in meningioma progression. The fact that inhibition of COX-2 by NSAIDs in meningioma cell lines decreased MIB-1 labeling index in tumor xenografts [33] supports our result. The prognostic value of COX-2 is still controversial, even for colorectal cancer. Although some previous results for colon cancer suggested COX-2 expression by cancer cells was associated with poor patient prognosis [24, 25] , another report indicated that COX-2 expression could not become an independent prognostic factor [26] . For meningeal tumor there was no previous prognostic report of COX-2 expression; we therefore examined the correlation of COX-2 expression level in tumor cells with overall survival and progression-free survival for 32 patients with high-grade meningioma. We divided the 32 cases into lowlevel (total score: less than 3) and high-level (total score: more than 4) of COX-2 (Table 3) , and analyzed them by the Kaplan-Meier method. As a result, there was no significant correlation between COX-2 expression level and patient prognosis, even for progression-free survival (Supplemental Fig. 4) , although we could not exclude the possibility that therapeutic differences might affect these results.
Currently there is no established standard chemotherapy for high-grade meningioma and recurrent benign meningioma. Molecular targeting therapy based on the different molecular alterations of meningioma tumorigenesis and progression is in high demand [34] . Expression of several growth factor receptors, including plateletderived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR), and basic fibroblast growth factor receptor (BFGFR) have been identified in meningioma [35] [36] [37] [38] ; however, clinical trials with molecular targeting drugs against such growth factor receptor revealed minimum efficacy [39] [40] [41] [42] [43] . COX-2 and its products, eicosanoids, are possible target molecules for cancer treatment [44] ; in fact, clinical benefit of administration of NSAIDs, for example aspirin and sulindac, to patients with familial adenomatous polyposis has been reported [45, 46] . In addition, several cohort studies revealed that use of NSAIDs, including aspirin, was significantly correlated with favorable patient prognosis in colon cancer [47] [48] [49] . With regard to the pharmacological target of NSAIDs, we should not ignore the involvement of inflammatory cells, for example macrophages and lymphocytes, in tumor stroma, because COX-2 is strongly induced in macrophages and other cells under conditions of inflammatory stimuli [50] . In addition, the positive feedback loop of COX-2 expression through PGE 2 and cAMP has previously been described in various types of non-cancerous cells, for example macrophages and vascular endothelial cells [51] . Necrosis is often observed for both atypical and anaplastic meningiomas, and can be accompanied by infiltrates of inflammatory cells, including neutrophils and macrophages, and a recent study showed the co-existence of CD45(-) neoplastic cells and CD45(?) immune infiltrating cells, including macrophages, in all meningiomas [52] . In fact, we recognized the infiltration of macrophages with COX-2 expression in stroma of meningioma during this analysis (Fig. 1) . The clinical benefit of NSAIDs usage for patients with malignant tumor might be a result of inhibition of the positive feedback loop of COX-2 expression among the tumor cells and inflammatory cells in stroma. Our results are giving us hope of treating patients with high-grade meningioma by use of NSAIDs in combination with another chemotherapeutic agents and/or radiation.
